Dr Reddy's Divests Svaas Wellness Stake to Enspirit for Rs 2.23 Crore
Hyderabad: Drugmaker Dr. Reddy's Laboratories Limited has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited, for a consideration of Rs 2.23 crore, as per a regulatory filing.
The company informed stock exchanges that the agreement for the sale was executed on April 7, 2026, and the transaction is also expected to be completed on the same day. Following the completion of this deal, Svaas Wellness Limited will cease to be a wholly owned subsidiary of Dr. Reddy’s Laboratories.
According to the disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Svaas Wellness Limited reported a turnover of Rs 28.5 crore as per its audited financials for FY 2025. Notably, 100% of this turnover was derived from Dr. Reddy’s Laboratories Limited, contributing approximately 0.09% to the company’s consolidated turnover.
The buyer in this transaction is Enspirit Technology Services Private Limited, based in Hyderabad, Telangana. The company clarified that the buyer does not belong to the promoter or promoter group or any group companies of Dr. Reddy’s Laboratories.
Further, the company confirmed that the transaction does not qualify as a related party transaction. Enspirit Technology Services Private Limited is not related to Dr. Reddy’s Laboratories or any of its subsidiaries, and the deal has been conducted independently.
The disclosure also stated that the transaction does not fall under a scheme of arrangement and is not categorized as a slump sale. Hence, additional regulatory requirements applicable to such cases are not relevant in this instance.
Dr. Reddy’s Laboratories, headquartered in Hyderabad, is a leading global pharmaceutical company engaged in providing affordable and innovative medicines. The divestment of Svaas Wellness Limited appears to be part of its strategic business decisions, though specific reasons for the sale were not disclosed in the filing.
Also Read: Dr Reddy's Partner Immutep Halts Phase III Trial of Eftilagimod Alfa in Lung Cancer Study
